Dr. Rider has invented a number of PANACEA (Pharmacological Augmentation of Nonspecific Anti-pathogen Cellular Enzymes and Activities) broad-spectrum therapeutics and conducted preliminary experiments demonstrating that those approaches are effective in cells and merit further development.

DRACO research is the core focus of the RIDER Institute.

Interested in DRACO? Click HERE.
At MIT, Dr. Rider invented the CANARY (Cellular Analysis and Notification of Antigen Risks and Yields) biosensor, which uses mammalian B lymphocyte cell lines stably transfected with the jellyfish aequorin gene to identify a wide variety of pathogens within seconds to minutes. Dr. Rider genetically engineered and demonstrated the first CANARY cells, and also invented second-generation CANARY approaches with multiple luminescence colors, polyclonal antibodies, and other improvements. CANARY was published in Science, reported everywhere from NBC’s Nightly News to Technology Review to The New York Times, and even featured in an episode of the science fiction TV series Helix.

Previously Dr. Rider invented CIGAR (Continual Improvement for Greater Advantage in Rocketry), an improved system of rocket staging that could increase a launch vehicle’s payload capacity by over 50% with no extra propellant. To demonstrate this approach, he wrote orbital flight simulations, tested scale models in a wind tunnel to verify aerodynamic stability of the new design, built small working models to evaluate key mechanical features of the design, and conducted static firing tests.

Dr. Rider has also proposed and explored novel approaches in other areas including biosensors, biofuel cells, DNA synthesizers, and other projects for various sponsors. The RIDER Institute is continuing to develop very innovative approaches to major scientific and technological challenges.